Promoting the Quality of Medicines Program, United States Pharmacopeia, Rockville, MD 20852, USA.
Malar J. 2012 Jun 15;11:202. doi: 10.1186/1475-2875-11-202.
Ensuring the quality of malaria medicines is crucial in working toward malaria control and eventual elimination. Unlike other validated tests that can assess all critical quality attributes, which is the standard for determining the quality of medicines, basic tests are significantly less expensive, faster, and require less skilled labour; yet, these tests provide reproducible data and information on several critical quality attributes, such as identity, purity, content, and disintegration. Visual and physical inspection also provides valuable information about the manufacturing and the labelling of medicines, and in many cases this inspection is sufficient to detect counterfeit medicines. The Promoting the Quality of Medicines (PQM) programme has provided technical assistance to Amazon Malaria Initiative (AMI) countries to implement the use of basic tests as a key screening mechanism to assess the quality of malaria medicines available to patients in decentralized regions.
Trained personnel from the National Malaria Control Programmes (NMCPs), often in collaboration with country's Official Medicine Control Laboratory (OMCL), developed country- specific protocols that encompassed sampling methods, sample analysis, and data reporting. Sampling sites were selected based on malaria burden, accessibility, and geographical location. Convenience sampling was performed and countries were recommended to store the sampled medicines under conditions that did not compromise their quality. Basic analytical tests, such as disintegration and thin layer chromatography (TLC), were performed utilizing a portable mini-laboratory.
Results were originally presented at regional meetings in a non-standardized format that lacked relevant medicines information. However, since 2008 information has been submitted utilizing a template specifically developed by PQM for that purpose. From 2005 to 2010, the quality of 1,663 malaria medicines from seven AMI countries was evaluated, mostly collected from the public sector, 1,445/1,663 (86.9%). Results indicate that 193/1,663 (11.6%) were found not to meet quality specifications. Most failures were reported during visual and physical inspection, 142/1663 (8.5%), and most of these were due to expired medicines, 118/142 (83.1%). Samples failing TLC accounted for 27/1,663 (1.6%) and those failing disintegration accounted for 24/1,663 (1.4%). Medicines quality failures decreased significantly during the last two years.
Basic tests revealed that the quality of medicines in the public sector improved over the years, since the implementation of this type of quality monitoring programme in 2005. However, the lack of consistent confirmatory tests in the quality control (QC) laboratory, utilizing methods that can also evaluate additional quality attributes, could still mask quality issues. In the future, AMI countries should improve coordination with their health authorities and their QC lab consistently, to provide a more complete picture of malaria medicines quality and support the implementation of corrective actions. Facilities in the private and informal sectors also should be included when these sectors constitute an important source of medicines used by malaria patients.
确保疟疾药物的质量对于疟疾控制和最终消除至关重要。与其他可以评估所有关键质量属性的经过验证的测试不同,这些测试是确定药物质量的标准,而基本测试的成本显著更低、速度更快且所需的技术劳动力更少;然而,这些测试可提供关于几个关键质量属性的可重复数据和信息,例如身份、纯度、含量和崩解。目视和物理检查还提供了有关药品制造和标签的有价值信息,在许多情况下,这种检查足以发现假药。促进药品质量(PQM)计划为亚马逊疟疾倡议(AMI)国家提供了技术援助,以实施基本测试作为关键筛选机制,以评估分散地区患者可获得的疟疾药物的质量。
国家疟疾控制规划(NMCP)的经过培训的人员(通常与国家官方药品控制实验室(OMCL)合作)制定了特定于国家的方案,其中包括采样方法、样品分析和数据报告。采样地点根据疟疾负担、可及性和地理位置选择。进行了便利抽样,建议各国在不影响药品质量的条件下储存采样药品。利用便携式迷你实验室进行基本分析测试,如崩解和薄层色谱(TLC)。
最初在区域会议上以非标准化格式呈现结果,缺乏相关药品信息。但是,自 2008 年以来,一直按照 PQM 专门为此目的开发的模板提交信息。2005 年至 2010 年,对来自七个 AMI 国家的 1663 种疟疾药物的质量进行了评估,其中大部分来自公共部门,有 1445/1663(86.9%)。结果表明,有 193/1663(11.6%)不符合质量规格。大多数失败是在目视和物理检查中报告的,有 142/1663(8.5%),其中大多数是由于过期药品,有 118/142(83.1%)。TLC 失败的样品占 1663 个(1.6%),崩解失败的样品占 1663 个(1.4%)。过去两年中,药品质量失败的情况显著减少。
基本测试显示,自 2005 年实施这种类型的质量监测计划以来,公共部门的药品质量多年来有所提高。但是,质量控制(QC)实验室中缺乏一致的确认测试,这些测试可利用评估其他质量属性的方法,仍可能掩盖质量问题。未来,AMI 国家应始终如一地加强与国家卫生当局及其 QC 实验室的协调,以更全面地了解疟疾药物的质量,并支持采取纠正措施。私营和非正规部门的设施也应包括在内,因为这些部门是疟疾患者使用的药品的重要来源。